Skip to main content
Premium Trial:

Request an Annual Quote

Barry Greene, John Maraganore, Lynne Parshall, David Haen, Ed Umali

Alnylam Pharmaceuticals said last week that COO Barry Greene will now serve as the company’s president. He will continue to serve as COO.
As president, Greene replaces John Maraganore, who will remain the company’s CEO.
Greene joined Alnylam in 2003, and will assume responsibility for the company’s business, corporate, and commercial development activities in his new role as president.

Isis Pharmaceuticals said last week that it has promoted Director and CFO Lynne Parshall to COO.
Parshall, who retains her position as CFO and director, joined Isis in 1991.

CytRx said this week that it has promoted David Haen to the position of vice president of business development. He was previously director of business development at the company.
CytRx also said that it has promoted Ed Umali, the company’s director of operations, to the role of vice president of operations.
Before joining CytRx, both Haen and Umali were investment bankers, according to the company.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.